Dr. Michael Ross joined SVLS as a Venture Partner in 2001, became a Managing Partner in 2002 and is based in San Francisco. Michael serves on the boards of Adimab, Alinea, Archemix, Intransasal, Itero Biopharmaceuticals, Link Medicine, Mpex, NKT Therapeutics, Sutro Pharmaceuticals and the Thayer School of Engineering (Dartmouth College). He has also served on the boards of Aderis Pharmaceuticals, Arris Pharmaceutical, Carta Proteomics, CyThera, Glycofi, Epimmune, Genencor, MetaXen, Rinat and Xenova.
Michael was the tenth employee at Genentech where he worked for 13 years. He served as Genentech team leader for HumulinÂ® (human insulin-Lilly), RoferonÂ® (Interferon alpha -Roche), ProtropinÂ® (hGH), Vice President of Development during the development of ActivaseÂ®, NutropinÂ® and PulmozymeÂ®. Michael then started Genentech’s protein engineering and small molecule discovery effort as Vice President of Medicinal and Biomolecular Chemistry. Michael was the Founding CEO of Arris Pharmaceutical, (now part of Celera), MetaXen, (now part of Exelixis), ExSAR and CyThera (now part of Novocell). Michael was most recently Managing Partner in Didyma, LLC, a biotechnology management consulting firm.